Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RARB | P10826 | 4/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13287468 | 0.92 | MAPK1 (0.85) | MAPK1RARBNR1H4PKMEPHX2 | |
| SCHEMBL6539739 | 0.91 | MAPK1 (0.84) | MAPK1RARBPKMTSHRTP53 | |
| SCHEMBL9813425 | 0.88 | RARB (0.88) | MAPK1RARBNR1H4PKMTSHR | |
| SCHEMBL10535460 | 0.88 | RARB (0.88) | MAPK1RARBNR1H4PKMTSHR | |
| SCHEMBL10535685 | 0.88 | RARB (0.88) | MAPK1RARBNR1H4PKMTSHR | |
| SCHEMBL10537317 | 0.88 | RARB (0.88) | MAPK1RARBNR1H4PKMTSHR | |
| SCHEMBL10334195 | 0.88 | RARB (0.88) | MAPK1RARBNR1H4PKMTSHR | |
| SCHEMBL15449670 | 0.88 | MAPK1 (0.77) | MAPK1RARBNR1H4PKMTSHR | |
| SCHEMBL10785289 | 0.88 | MAPK1 (0.77) | MAPK1RARBNR1H4PKMTSHR | |
| SCHEMBL28520501 | 0.88 | MAPK1 (0.77) | MAPK1RARBNR1H4PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| CN-109054648-A | Serosity combination for chemically mechanical polishing | LTCAM有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-9869027-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| US-9700543-B2 | GLP-1 receptor stabilizers and modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-07-11 | — | — | US | disclosed |
| EP-2713722-B1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160310471-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2016-10-27 | — | — | US | disclosed |
| US-20160230289-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9340759-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-05-17 | — | — | US | disclosed |
| US-9278910-B2 | GLP-1 receptor stabilizers and modulators | RECEPTOS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009131274-A1 | SYNTHESIS OF PHOTOINITIATOR FREE REACTIVE MESOGENS BASED ON TRIPHENYLENE | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-29 | — | — | WO | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0454501-B1 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | SANKYO CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-0839812-A1 | Preparation of benzylthiazolidine derivatives | Sankyo Company Limited (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5387596-A | Treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0454501-A2 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | Sankyo Company Limited (JP) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310471-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | GLP1R, GIPR, GHSR | MAPK1 1370/4885RARB 2721/4885NR1H4 1673/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | MAPK1 1483/4885RARB 322/4885NR1H4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.